Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1731-1737

  Nieto, Yago ^a,c   Cagnoni, Pablo J ^a   Shpall, Elizabeth J ^a   Matthes, Steve ^a   Barón, Anna ^b   Jones, Roy B ^a   Bearman, Scott I ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Biostatistics ^*  (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLON HEMORRHAGE; DRUG MEGADOSE; FEMALE; HEMORRHAGIC SHOCK; HUMAN; OPTIC NERVE DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032781922     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Harris, J., Morrow, M., and Norton, L. Malignant tumors of the breast. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 1602-1603. Philadelphia: Lippincott-Raven, 1997.
2. Greenberg, P. A. C., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., and Buzdar, A. U. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol., 14: 2197-2205, 1996.
3. Frei, E., III, and Canellos, G. P. Dose. A critical factor in cancer chemotherapy. Am. J. Med., 69: 585-594, 1980.
4. Frei, E., III, Antman, K., Teicher, B., Eder, P., and Schnipper, L. Bone marrow autotransplantation for solid tumors: prospects. J. Clin. Oncol., 4: 515-526, 1989.
5. Peters, W. P., Shpall, E. J., Jones, R. B., Olsen, G. A., Bast, R. C., Gockerman, J. P., and Moore J. O. High-dose combination chemotherapy with bone marrow support as initial treatment for metastatic breast cancer. J. Clin. Oncol., 6: 1368-1376, 1988.
6. Jones, R. B., Shpall, E. J., Ross, M., Bast, R., Affronti, M., and Peters, W. P. AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer: current results. Proc. Am. Soc. Clin. Oncol., 7: 121, 1990.
7. Antman, K., Ayash, L., Elias, A., Wheeler, C., Hunt, M., Eder, J. P., Teicher, B. A., Critchlow, J., Bibbo, J., Schnipper, L. E., and Frei, E., III. A Phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J. Clin. Oncol., 10: 102-110, 1992.
8. Williams, S. F., Gilewski, T., Mick, R., and Bitran, J. D. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow-up report. J. Clin. Oncol., 10: 1743-1747, 1992.
9. Rahman, Z. U., Frye, D. K., Buzdar, A. U., Smith, T. L., Asmar, L., Champlin, R. E., and Hortobagyi, G. N. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J. Clin. Oncol., 15: 3171-3177, 1997.
10. Swenerton, K. D., Legha, S. S., Smith, T., Hortobagyi, G. N., Gehan, E. A., Yap, H-Y., Gutterman, J. U., and Blumenschein, G. R. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res., 39: 1552-1562, 1979.
11. Dunphy, F. R., Spitzer, G., Rossiter Fornoff, J. E., Yau, J. C., Huan, S. D., Dicke, K. A., Buzdar, A. U., and Hortobagyi, G. N. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer (Phila.), 73: 2157-2167, 1994.
12. Ayash, L. J., Wheeler, C., Fairclough, D., Schwartz, G., Reich, E., Warren, D., Schnipper, L., Antman, K., Frei, E., III, and Elias, A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J. Clin. Oncol., 13: 2043-2049, 1995.
13. Doroshow, J. H., Somlo, G., Ahn, C., Baker, P., Rincon, A., Forman, S., Akman, S., Chow, G., Coluzzi, P., Hamansaki, V., Leong, L., Margolin, K., Molina, A., Morgan, R., Raschko, J., Shibata, S., Tetef, M., Yen, Y., and Brent, J. Prognostic factors predicting progression-free and overall survival in patients with responsive metastatic breast cancer treated with high-dose chemotherapy and bone marrow stem cell reinfusion. Proc. Am. Soc. Clin. Oncol., 14: 319a, 1995.
14. Rizzieri, D. A., Vredenburgh, J. J., Chao, N. J., Broadwater, G., Berry, D., and Peters, W. P. Prognostic factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high dose therapy with hematopoietic support. Blood, 92 (Suppl. 1): 462a, 1998.
15. Krause, D. S., Fackler, M. J., Civin, C. I., and Stratford May, W. CD34: structure, biology, and clinical utility. Blood, 87: 1-13, 1996.
16. Shpall, E. J., Jones, R. B., Bearman, S. I., Franklin, W. A., Archer, P. G., Curiel, T., Bitter, M., Claman, H. N., Stemmer, S. M., Purdy, M., Myers, S. E., Hami, L., Taffs, S., Heimfeld, S., Hallagan, J., and Berenson, R. J. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J. Clin. Oncol., 12: 28-36, 1994.
17. Shpall, E. J., LeMaistre, C. F., Holland, K., Ball, E., Jones, R. B., Saral, R., Jacobs, C., Heimfeld, S., Berenson, R., and Champlin, R. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood, 90: 4313-4320, 1997.
18. Jones, R. B., Matthes, S., Dufton, C., Bearman, S. I., Stemmer, S. M., Myers, S. E., and Shpall, E. J. Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin and BCNU in patients with breast cancer. Breast Cancer Res. Treat., 26: S11-S17, 1993.
19. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Med. Assoc., 53: 457-481, 1958.
20. Peto, R., and Peto J. Asymptomatically efficient rank invariant test procedures. J. R. Stat. Soc. A, 135: 185-198, 1971.
21. Cox, D. R. Regression models and life tables. J. R. Stat. Soc. B, 34: 187-202, 1972.
22. Jones, R. B., Matthes, S., Shpall, E. J., Fisher, J. H., Stemmer, S. M., Dufton, C., Stephens, J. K., and Bearman, S. I. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin and carmustine: pharmacodynamic evaluation of carmustine. J. Natl. Cancer Inst. (Bethesda), 85: 640-647, 1993.
23. Peters, W. P., Berry, D., Vredenburgh, J. J., Hussein, A., Rubin, P., Elkordy, M., Ross, M., Henderson, I. C., Budman, D., Norton, L., Weiss, R., and Hurd, D. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥ 10 axillary lymph nodes (Duke/ CALGB 8782). Proc. Am. Soc. Clin. Oncol., 14: 317a, 1995.
24. Gianni, A. M., Siena, S., Bregni, M., Di Nicola, M., Orefice, S., Cusumano, F., Salvadori, B., Luini, A., Greco, M., Zucali, R., Rilke, F., Zambetti, M., Valagussa, P., and Bonadonna, G. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary lymph nodes: five year results. J. Clin. Oncol., 15: 2312-2321, 1997.
25. Bearman, S. I., Overmoyer, B. A., Bolwell, B. J., Taylor, C. W., Shpall, E. J., Cagnoni, P. J., Mechling, B. E., Ronk, B., Barón, A. E., Purdy, M. H., Ross, M., and Jones, R. B. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplant., 20: 931-937, 1997.
26. Ayash, L. J., Elias, A., Ibrahim, J., Schwartz, G., Wheeler, C., Reich, E., Lynch, C., Warren, D., Shapiro, C., Richardson, P., Hurd, D., Schnipper, L., Frei, E., III, and Antman, K. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J. Clin. Oncol., 16: 1000-1007, 1998.
27. Cagnoni, P. J., Nieto, Y., Shpall, E. J., Bearman, S. I., Barón, A. E., Ross, M., Matthes, S. M., Dunbar, S. E., and Jones, R. B. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J. Clin. Oncol., 16: 1661-1668, 1998.
28. Saphner, T., Tormey, D. C., and Gray, R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol., 14: 2738-2746, 1996.
29. Budman, D. R., Berry, D. A., Cirrincione, C. T., Henderson, I. C., Wood, W. C., Weiss, R. B., Ferree, C. R., Muss, H. B., Green, M. R., Norton, L., and Frei, E., III. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J. Natl. Cancer Inst. (Bethesda), 90: 1205-1211, 1998.
30. Kritz, A., Crown, J., Motzer, R. J., Reich, L. M., Heller, G., Moore, M. P., Hamilton, N., Yao, T. J., Heelan, R. T., Schneider, J. G., Moore, M. A. S., McCormick, B., Gilewski, T., O'Reilly, R. J., Gulati, S. C., and Norton, L. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. Cancer (Phila.), 71: 2515-2521, 1993.
31. Chao, N. J., Schriber, J. R., Grimes, K., Long, G. D., Negrin, R. S., Raimondi, C. M., Horning, S. J., Brown, S. L., Miller, L., and Blume, K. G. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood, 81: 2031-2035, 1993.
32. Ayash, L. J., Wright, J. E., Tretyakov, O., Gonin, R., Elias, A., Wheeler, C., Eder, J. P., Rosowsky, A., Antamn, K., and Frei, E., III. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J. Clin. Oncol., 10: 995-1000, 1992.
33. Falkson, G., Gelman, R., Falkson, C. I., Glick, J., and Harris, J. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J. Clin. Oncol., 9: 2153-2161, 1991.
34. Buzdar, A. U., Legha, S. S., Hortobagyi, G. N., Yap, H. Y., Wiseman, C. L., DiStefano, A., Schell, F. C., Barnes, B. C., Campos, L. T., and Blumenschein, G. R. Management of breast cancer patients failing adjuvant chemotherapy with Adriamycin-containing regimens. Cancer (Phila.), 47: 2798-2802, 1981.
35. Buzdar, A. U., Blumenschein, G. R., Montague, E. D., and Hortobagyi, G. N. Combined modality approach in breast cancer with isolated or multiple metastases. Am. J. Clin. Oncol., 6: 45-50, 1983.
36. Holmes, F. A., Buzdar, A. U., Kau, S-W., Fraschini, G., Ames, F. C., McNeese, M. D., and Hortobagyi, G. N. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED). The M. D. Anderson experience. Breast Dis., 7: 7-20, 1994.
37. Blumenschein, G. R., DiStefano, A., Caderao, J., Firstenberg, B., Adams, J., Schweichler, L. H., and Drinkard, L. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistant late-consolidation chemotherapy. Clin. Cancer Res., 3: 2633-2637, 1997.
38. Kennedy, M. J., and Abeloff, M. D. Management of locally recurrent breast cancer. Cancer (Phila.), 71: 2395-2409, 1993.
39. Recht, A., Hayes, D. F., Eberlein, T. J., and Sadowsky, N. L. Local-regional recurrence after mastectomy or breast-conserving therapy. In: J. R. Harris, M. E. Lippman, M. Morrow, and S. Hellman (eds.), Diseases of the Breast, pp. 649-667. Philadelphia: Lippincott-Raven, 1996.
40. Janjan, N. A., McNeese, M. D., Buzdar, A. U., Montague, E. D., and Oswald, M. J. Management of locoregional recurrent breast cancer. Cancer (Phila.), 58: 1552-1556, 1986.
41. Halverson, K. J., Perez, C. A., Kuske, R. R., Garcia, D. M., Simpson, J. R., and Fineberg, B. Locoregional recurrence of breast cancer: a retrospective comparison of irradiation alone versus irradiation and systemic therapy. Am. J. Clin. Oncol., 15: 93-101, 1992.
42. Beck, T. M., Hart, N. E., Woodard, D. A., and Smith, C. E. Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. J. Clin. Oncol., 1: 400-405, 1983.
43. Toonkel, M., Fix, I., Jacobsen, L. H., and Wallach, C. B. The significance of local recurrence of carcinoma of the breast. Int. J. Radiat. Oncol. Biol. Phys., 9: 33-39, 1983.
44. Bedwinek, J. M., Fineberg, B., Lee, J., and Ocwieza, M. Analysis of failures following local treatment of isolated local-regional recurrence of breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 7: 581-585, 1981.
45. Borner, M., Bacchi, M., Goldhirsch, A., Greiner, R., Harder, F., Castiglione, M., Jungi, W. F., Thürlimann, B., Cavalli, F., Obrecht, J. P., Leyvraz, S., Alberto, P., Adam, H., Varini, M., Loehnert, T., Semm, H. J., Metzger, U., and Brunner, K. First isolated locoregional recurrence following mastectomy for breast cancer: results of a Phase III multicenter study comparing systemic treatment with observation after excision and radiation. J. Clin. Oncol., 12: 2071-2077, 1994.